# A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India

Study · id `cardio:ct-nct04153981` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04153981](<https://clinicaltrials.gov/study/NCT04153981>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04153981

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 304 participants.

## Technical summary

Registry record NCT04153981. Allocation not applicable; no masking; primary purpose treatment. Start 2019-12-16 (actual); primary completion 2021-07-30 (actual). Results posted on 2024-02-15.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 304 participants (enrolled count; ClinicalTrials.gov record NCT04153981, source copy `cardio:ctgov-nct04153981-2024-02-15`, retrieved 2026-10-26)
- Started: 2019-12-16 (actual) (ClinicalTrials.gov record NCT04153981, source copy `cardio:ctgov-nct04153981-2024-02-15`, retrieved 2026-10-26)
- Primary completion: 2021-07-30 (actual) (ClinicalTrials.gov record NCT04153981, source copy `cardio:ctgov-nct04153981-2024-02-15`, retrieved 2026-10-26)
- Completion: 2021-07-30 (actual) (ClinicalTrials.gov record NCT04153981, source copy `cardio:ctgov-nct04153981-2024-02-15`, retrieved 2026-10-26)
- Results first posted: 2024-02-15 (ClinicalTrials.gov record NCT04153981, source copy `cardio:ctgov-nct04153981-2024-02-15`, retrieved 2026-10-26)
- Countries: India (ClinicalTrials.gov record NCT04153981, source copy `cardio:ctgov-nct04153981-2024-02-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04153981-2024-02-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Insulin Glargine
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 1b4da8e271929b20e769fc580f2250adb4507916120f8f16a2d900828caf363f
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
